1Horn LC, Klostermann K, Hautmann S, et al. HPV-associated altera- tions of the vulva and vagina[ J]. Pathologe,2011,32 :467 -475.
2Smith JS, Backes DM, Hoots BE, et al. Human papillomavirus type- distribution in vulvar in vulvar and vaginal cancer and theis associated precursors [ J ]. Obstet Gyneco1,2009,113 (4) :917 - 924.
3Choschzick M, Hantaredja W,Tennstedt P, et al. Role of TP53 muta- tions in vulvar carcinomas [ J ]. Int J Gynecol Pathol, 2011,30 (5) : 497 - 504.
4Ueda Y, Enomoto T, Kimura T, et al. Two distinct pathways to devel- opment of squamous cell carcinoma of the vulva [ J ]. J Skin Cancer, 2011 : 951250.
5Lopez-Ocejo O, Viloria-Petit A, Bequet-Romero M. Onco-genes and tumor angiogenesis: the HPV-16 E6 oncoprotei activates thevascular endothelialgroeth factor(VEGF) gene promotor in a p53 independent manner [ J ]. Oncogene,2000,19 (40) :4611 - 4620.
6van der Avoort IA, van de Nieuwenhof HP, Otte-Hiiller 1, et al. High levels of p53 expression correlate with DNA aneuploidy in (pre)ma- lignancies of the vulva[ J]. Hum Patho1,2010,41 (10) :1475 -1485.
7Choschzick M, Hantaredja W, Tennstedt P, et al. Role of Tt3 muta- tions in vulvar carcinomas [ J ]. Int J Gynecol Pathol, 2011,30 ( 5 ) : 497 - 504.
9van de Nieuwenhof HP, Buhen J, Hollema H, et al. Differentiated vul- var intraepithelial neoplasia is often found in lesions, previously diag- nosed as lichen sclerosus, which have progressed to vulvar squamouscell carcinoma [ J ]. Mod Patho1,2011,24 (2) :297 - 305.
10McPherson T, Cooper S, Dermatol Ther, et al. Vulval lichen sclerosus and lichen planus [ J ]. Dermatol Ther,2010,23 (5) :523 - 532.
5Canavan T P, Cohen D. Vulvar cancer [J]. Am Fam Physician, 2002; 66 (7) : 1269-1274.
6Ferrandina G, Ranelhtti F O, Salutari V et al. Expression of cyclooxygenase-2 (COX-2) in non-neoplastic and neoplastic vulvar epithelial, lesions [ J ]. Gynecol Oncol, 2004; 92( 2 ) : 537-544.
7Ben-Hur H, Ashkenazi M, Huszar M et al. Lymphoid elements and apoptosis-related proteins (Fas, Fas ligand, p53 and bcl-2) in lichen sclerosus and carcinoma of the vulva[J] .Eur J Gynaecol Oncol,2001 ;22(2):104- 109.
8Oyama N, Chan I,Neill S M et al. Autoantibodies to extracellular matrix protein 1 in lichen sclerosus[J]. Lancet,2003;362(9378) : 1118-1123.
9Sander C S, Ali I, Dean D et al. Oxidative stress is implicated in the pathogenesis of lichen sclerosus [ J ]. Br J Dermatol, 2004; 151 (3) : 627- 635.
10Farrell A M, Marren P, Dean D et al. Lichen sclerosus: evidence that immunological changes occur at all levels of the skin[J]. Br J Dennatol, 1999; 140(6) : 1087-1092.
5Terga A I.Tseng J H, Bristow RE. Impact of race and eth-nicity on treatment and survival of women with vulvar cancerin the United States[J], Gynecol Oncol,2013,129 (1) : 154-158.
6Nogawa T,Hiura M. Treatment of vulvar and vaginal cancer[J]. Nihon Rinsho,2012,70 (4):687-691.
7Lee J, Kim SH.Kim Gyet al. Treatment outcome in patientswith vulvar cancer: comparison of concurrent radiotherapy topostoperative radiotherapy[J]. Radiat Oncol J.2012, 30( 1) .20-26.
